U.S. FDA Approves Merck ’s Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children

Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four-dose series and superior immune responses for important disease-causing shared serotype 3 and unique serotypes 22F...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news